Assessment of Breast Cancer Risk with High Spectral and Spatial Resolution MRI

使用高光谱和空间分辨率 MRI 评估乳腺癌风险

• 批准号: 8792350
• 负责人: Gregory S. Karczmar
• 金额: $ 48.9万
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-02-08 至 2016-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8792350
• 关键词: 3-Dimensional; Affect; Age; Bilateral; Breast; Breast Cancer Risk Factor; Classification; Clinical; Computer Assisted; Computer software; Computer-Assisted Diagnosis; Development; Evaluation; Fatty acid glycerol esters; Goals; Image; Individual; Laboratories; Magnetic Resonance Imaging; Mammographic Density; Mammography; Measurement; Measures; Methods; Morphology; Patients; Performance; Pharmaceutical Preparations; Physiologic pulse; Preventive; Protons; Raloxifene; Research; Resolution; Risk; Risk Management; Risk Marker; Roentgen Rays; Selective Estrogen Receptor Modulators; Signal Transduction; Tamoxifen; Testing; Texture; Therapeutic Agents; Three-Dimensional Imaging; Validation; Variant; Visual; Water; Woman; Work; base; breast density; cancer risk; density; effective therapy; imaging modality; improved; innovation; malignant breast neoplasm; novel; novel marker; novel therapeutics; population based; public health relevance; response; saturated fat; spectroscopic imaging; tool; treatment planning

DESCRIPTION (provided by applicant): We propose to test whether HiSS MRI estimates breast cancer risk more accurately than conventional fat- suppressed MRI and X-ray mammography. Reliable measurements of breast density, which is one of the strongest independent risk factors for breast cancer, could significantly improve management of risk and preventive treatment. X-ray mammography predicts increased cancer risk on a population basis but has limited value for guiding treatment of individual patients, due to errors in separation of parenchyma and fat, and errors in measurement of the parenchymal volume. MRI allows 3D imaging of breast parenchyma and detects independent signals from water and fat. MRI detects significant decreases in breast density due to tamoxifen and raloxifen. However, conventional MRI requires suppression of signals from fat in the breast. Fat suppression is sometimes non-uniform and fat suppression pulses affect the water resonance, reducing the accuracy of parenchymal volume measurements. Therefore we propose an innovative approach to measurement of breast cancer risk: We will use high spectral and spatial resolution MR imaging (HiSS MRI) to reliably separate water and fat signals, and to quantitatively measure parenchymal density and changes in breast density due to tamoxifen. We hypothesize that use of quantitative HiSS imaging will reduce variability, standardize measurements, and increase sensitivity to variations in parenchymal volume. In addition, HiSS may provide new markers for risk based on the novel computer-aided diagnosis (CAD) analysis of the enhanced texture of HiSS images, and HiSS images of fat distribution. This proposal builds on work in this laboratory that implemented HiSS MRI on clinical magnets and demonstrated significant advantages of this approach. We propose the following Specific Aims: Aim #1: Implement quantitative full bilateral measurements of breast parenchymal density and morphology with HiSS MRI. Phantoms attached to the breast will be used to accurately measure MRI- detectable proton density. Novel software will evaluate parenchymal volume and texture. Fat distribution and composition will be tested as additional markers for risk. Aim #2. Compare HiSS with conventional approaches: We will compare breast density measured with HiSS, conventional fat-suppressed MRI, Dixon MRI methods, and X-ray mammography. Measures of breast density will include absolute and fractional parenchymal volume, and MRI-detectable water proton density. The variability of HiSS and conventional MRI measurements will be compared. Aim #3. Measure changes in parenchymal density due to selective estrogen receptor modulator (SERM) therapy: As a measure of the sensitivity of HiSS MRI to changes in breast cancer risk, we propose to image response to preventive therapy that is known to reduce risk. We will compare the sensitivity of HiSS MRI to effects of tamoxifen therapy with that of 2D X-ray mammography and conventional MRI.

描述（由申请人提供）：我们建议测试HISS MRI估计乳腺癌是否比常规脂肪抑制的MRI和X射线乳房X线摄影更准确。可靠的乳房密度测量是乳腺癌的最强独立危险因素之一，可以显着改善风险和预防治疗的管理。 X射线乳房X线摄影预测，由于实质和脂肪分离的错误以及实质体积的测量错误，X射线X线摄影预测人群中的癌症风险增加，但指导单个患者的指导治疗价值有限。 MRI允许对乳腺实质进行3D成像，并检测到水和脂肪的独立信号。 MRI检测到由于他莫昔芬和拉洛昔芬引起的乳房密度显着降低。但是，常规MRI需要抑制乳房中脂肪的信号。脂肪抑制有时是不均匀的，脂肪抑制脉冲会影响水共振，从而降低了实质体积测量的准确性。因此，我们提出了一种用于测量乳腺癌风险的创新方法：我们将使用高光谱和空间分辨率MR成像（HISS MRI）可靠地分离水和脂肪信号，并定量测量实质密度以及由于他莫昔芬引起的乳房密度变化。我们假设使用定量HISS成像将降低可变性，标准化测量值并增加对实质体积变化的敏感性。此外，HIS可能会根据新型计算机辅助诊断（CAD）分析hiss图像的增强纹理以及脂肪分布的嘶嘶声图像提供新的风险标记。该提案以该实验室的工作为基础，该实验室在临床磁铁上实施了HISS MRI，并证明了这种方法的显着优势。我们提出以下特定目的：目标＃1：使用HISS MRI实施乳腺实质密度和形态的定量完全双边测量。附着在乳房上的幻影将用于准确测量可检测到的质子密度。新颖的软件将评估实质的体积和质地。脂肪的分布和成分将作为风险的其他标记进行测试。目标＃2。将HIS与常规方法进行比较：我们将比较用Hiss，常规脂肪抑制的MRI，Dixon MRI方法和X射线乳房X线摄影测量的乳房密度。乳房密度的度量将包括绝对和分数实质体积以及MRI可检测水质子密度。将比较HIS和常规MRI测量的可变性。目标＃3。测量因选择性雌激素受体调节剂（SERM）治疗引起的实质密度的变化：作为衡量HISS MRI对乳腺癌风险变化的敏感性的量度，我们建议对已知降低风险的预防疗法的反应进行图像反应。我们将比较HISS MRI与他莫昔芬疗法的影响与2D X射线乳房X线摄影和常规MRI的敏感性。